Dulaglutide Cuts Weight Gain After Smoking Cessation
By Lori Solomon HealthDay Reporter
FRIDAY, Dec. 22, 2023 -- Dulaglutide cuts post-smoking cessation weight gain in men and women, according to a study published online Dec. 19 in BMJ Nutrition, Prevention & Health.
Fabienne Baur, M.D., from University Hospital Basel in Switzerland, and colleagues investigated gender differences in weight change after dulaglutide-assisted smoking cessation. The analysis included 255 adults who smoked daily (155 women and 100 men) who were randomly assigned to weekly dulaglutide (1.5 mg) or placebo (0.9 percent sodium chloride) in addition to standardized smoking cessation care (varenicline 2 mg/day plus behavioral counseling) for 12 weeks.
The researchers observed no gender differences in absolute or relative weight change for either dulaglutide or placebo treatment. In the placebo group, substantial weight gain (>6 percent increase) was almost five times more frequent in women than men (24 versus 5 percent). On dulaglutide, female participants were less likely to have substantial weight gain versus those treated with placebo (1 versus 24 percent). This dulaglutide effect was less pronounced in men (0 versus 5 percent).
"Our results underline the efficacy of dulaglutide in preventing postcessation weight gain in both genders and particularly in women who appear to be more prone to substantial weight gain than men," the authors write.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted December 2023
Read this next
Adiposity in Adulthood Linked to Adverse Cardiac Structure, Function
WEDNESDAY, July 17, 2024 -- Higher adiposity over adulthood is associated with adverse cardiac structure and function, according to a study published online July 16 in the...
Obesity Modifies Link Between Birth Weight, Metabolic Phenotypes
TUESDAY, July 16, 2024 -- Associations between lower birth weight (BW) and adverse metabolic phenotypes are more pronounced in children with obesity, according to a study...
Only One-Quarter of Patients Still Taking Semaglutide for Weight Loss Two Years Later
FRIDAY, July 12, 2024 -- Three of four patients stop taking semaglutide (Ozempic or Wegovy) two years after being prescribed the glucagon-like peptide-1 receptor agonist (GLP-1...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.